<?xml version="1.0" encoding="UTF-8"?>
<p>Australia has a long history of a partnership response to HIV and hepatitis C, comprising a collaborative network of policy jurisdictions, health services, community organizations, and researchers. However, these networks are now havin to adapt to the largest and most rapid changes in the nature of these epidemics for decades. These changes include unprecedented developments in prevention and treatment technologies, including major policy and practice shifts to prioritize the use of treatment as prevention in HIV and HCV (
 <xref rid="B1" ref-type="bibr">1</xref>–
 <xref rid="B3" ref-type="bibr">3</xref>). This is where people infected with the virus are encouraged to seek treatment for both their personal benefit and for the broader public health benefit of reducing viral transmission (
 <xref rid="B4" ref-type="bibr">4</xref>, 
 <xref rid="B5" ref-type="bibr">5</xref>). This growing prominence of clinical interventions and services for prevention is accentuated further in HIV, where drugs used to treat people living with HIV are now being used by people without HIV to stop them acquiring HIV—known as pre-exposure prophylaxis (PrEP) (
 <xref rid="B6" ref-type="bibr">6</xref>).
</p>
